If you or a loved one developed progressive multifocal leukoencephalopathy (PML) while on Tysabri, understanding the diagnostic process is critical. The clinical workup—including MRI and lumbar puncture—helps confirm the diagnosis, but no single test is definitive. This page explains what testing can and cannot reveal, building on decades of medical research into drug-associated neurological risks.
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Virginia who have developed PML after Tysabri treatment, understanding the medical evidence, risk factors, and legal considerations—including the statute of limitations—is critical. PML is an opportunistic viral infection of the brain that typically occurs only in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation varies but commonly includes progressive neurological deficits such as weakness, visual disturbances, cognitive decline, ataxia, and speech difficulties. Diagnosis is confirmed through brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid via PCR, or through brain biopsy. Early recognition is essential because Tysabri must be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier. This mechanism reduces inflammation in the central nervous system but also impairs immune surveillance, creating an environment where JC virus can reactivate and cause PML. The prescribing information includes a boxed warning stating that Tysabri increases the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of this risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients must be enrolled, read the Medication Guide, understand the risks, and sign a Patient Enrollment Form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The development of PML in Tysabri-treated patients is linked to three established risk factors: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Anti-JCV antibodies indicate prior exposure to the JC virus; patients who are seropositive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The duration of therapy is a critical factor, with risk increasing significantly after two years of continuous treatment. Prior immunosuppressant use further elevates risk by compounding immune suppression. These factors should be considered in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The prescribing information for Tysabri includes a boxed warning that clearly states the increased risk of PML and identifies the three risk factors. Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, questions may arise about whether the warnings were adequate in specific cases, particularly if patients were not fully informed of the risk or if monitoring protocols were not followed. The TOUCH program is designed to ensure that patients understand the risks, but compliance and communication can vary.
For patients in Virginia who have developed PML after Tysabri treatment, settlement considerations may include the severity of the injury, the timeline between exposure and documented harm, and the adequacy of warnings provided. PML usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), so damages can be substantial, covering medical expenses, lost income, and pain and suffering. The statute of limitations for filing a lawsuit in Virginia is generally two years from the date the injury was discovered or reasonably should have been discovered. This means that patients or their families must act promptly after a PML diagnosis to preserve their legal rights. Settlement negotiations may consider the strength of the evidence linking Tysabri to the patient's PML, the presence of risk factors, and whether the treating physician adhered to monitoring and warning protocols.
The onset of PML can occur after a few months to several years of Tysabri treatment. The risk increases with longer treatment duration, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Documented harm is typically confirmed through MRI and CSF analysis. The timeline is important for legal purposes because it affects when the statute of limitations begins to run. In Virginia, the clock starts when the patient knows or should know of the injury and its cause. Early diagnosis and documentation are crucial for both medical management and legal claims.
Tysabri-associated PML is a devastating condition with a high rate of death or severe disability. The medical evidence clearly identifies risk factors and mandates monitoring and immediate discontinuation at the first sign of PML. For Virginia patients, the statute of limitations imposes a strict deadline for filing claims, making timely legal consultation essential. Settlement considerations will depend on the specific facts of each case, including the adequacy of warnings and the timeline of harm.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Virginia, the statute of limitations for personal injury claims, including those related to Tysabri and PML, is generally two years from the date the injury was discovered or reasonably should have been discovered. It is crucial to consult with an attorney promptly after a PML diagnosis to ensure your claim is filed within this timeframe.
The three established risk factors for PML in Tysabri-treated patients are: presence of anti-JCV antibodies (indicating prior JC virus exposure), longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.